GSKVX000000070965

GSKVX000000070965 is an experimental influenza vaccine candidate developed by GSK (GlaxoSmithKline Biologicals). It is designed to provide protection against seasonal influenza viruses. While specific details regarding its exact formulation (such as whether it is a recombinant protein, mRNA, or inactivated virus) are often proprietary in early development, GSK's influenza pipeline typically focuses on improving the breadth and durability of the immune response, often utilizing their proprietary adjuvant systems (like AS03) or novel platform technologies. The candidate is intended to induce neutralizing antibodies against the hemagglutinin protein of circulating influenza strains to prevent infection and reduce disease severity.